
BioAlma and I are thinking partners for biotech founders. BioAlma is the intelligence platform and I’m its human operator. AI can now do much of the information work in a biotech. What it cannot supply is initiative, experience and aspiration. That’s where I come in.
I have sat in your seat: needing a sharp read on the competitive landscape, quickly, without a six-figure platform contract and a training program to learn it.
That is the real difference. The big intelligence vendors sell you software and leave you alone with it, with no one to call and no one to ask “can you cut this another way?” With BioAlma, I build your intelligence boards myself, and I am on the other end: to talk through what the data means, refine a view, or run a new analysis the moment your questions change.
“The big platforms give you software. I give you the analysis, and a real person to ask when you need it cut another way.”
On BioAlma’s cloud, or on a server your company owns, secured and encrypted, with your own sign-in.
Competitors, trials, investigators, key opinion leaders, regulatory precedent: shaped around the decisions in front of you.
Your records indexed, searchable and cited back to the source page, mapped to what you are building toward, such as a regulatory submission.
Agents track new publications, trial updates, competitor moves and the commitments you have made, so nobody has to remember.
A standing meeting where the intelligence meets experience: what changed, what it means, what to do about it.
A monthly written summary of the work done and the hours spent. No surprises.
I trained in neurology, neuroscience and business. At Artiva Biotherapeutics I was responsible for financial planning through the company’s IPO, and then for medical and competitive intelligence. Before that, I built and led ventures in medicine and clinical research in Brazil and the US.
My whole career has been built on demanding relationships: with physicians as a hospital’s chief medical officer, with investors and corporate clients as a consultant and an entrepreneur. Trust is what makes intelligence useful.
Along the way I have worked with Novartis, Roche, Ionis, Bain, the Economist Intelligence Unit, Pátria and the IFC, and with the hospitals and founders who taught me most of what I know.
What you are building, what decisions are coming, what information you are missing.
A plan, options and costs in one place, written for your team to review.
Installed where you choose, connected to your documents, with your own AI account if you prefer.
The dashboards and the library grow with the work; our meeting keeps them pointed at what matters.
Simple terms: an hourly rate with a monthly minimum that also covers the platform. Infrastructure and AI usage can sit in your own accounts, so you see every cost directly.
BioAlma runs on a server the company owns, reads from its own document store and uses its own AI account. I set up the instance, the sign-in and the encrypted data area within days of signing; next, years of records become one cited library.
Client details shared only with permission.
Trust built into the architecture, not promised in a slide.
If you choose your own server, it is in your company’s name. If we stop working together, you keep everything and can keep running it.
The in-app agent can run on your own AI provider account, under commercial terms that do not train on your data.
I get the access the work needs and nothing more. Your administrators control it.
Your name, your data and your plans are never used to sell to anyone else.
Thirty minutes is enough to know whether working together makes sense for your company.